Royalty Pharma (RPRX) CFO-linked entity sells 64,399 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported an open-market sale of 64,399 Class A Ordinary Shares on May 26, 2026 at a weighted average price of $53.9778 per share, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, that entity held no remaining shares, while other reported direct and indirect accounts continued to hold Class A Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 64,399 shares ($3,476,116)

Net Sell 5 txns

Insider Coyne Terrance P.

Role EVP & CFO

Sold 64,399 shs ($3.48M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	64,399	$53.9778	$3.48M
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 0 shares (Indirect, TPC RP EPA1 LLC); Class A Ordinary Shares — 1,500 shares (Direct, null)

Footnotes (1)

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 64,399 shares Weighted average sale price: $53.9778 per share Sale price range: $53.64–$54.63 per share +5 more

8 metrics

Shares sold 64,399 shares Open-market sale by TPC RP EPA1 LLC on May 26, 2026

Weighted average sale price $53.9778 per share Class A Ordinary Shares sold on May 26, 2026

Sale price range $53.64–$54.63 per share Range of prices for multiple sale transactions

Direct holdings after transactions 1,500 shares Direct Class A Ordinary Shares held following reported transactions

Spouse holdings after transactions 1,450 shares Indirect ownership via spouse after reported transactions

IRA holdings after transactions 23,270 shares Indirect ownership via IRA after reported transactions

Spouse's IRA holdings after transactions 24,170 shares Indirect ownership via spouse's IRA after reported transactions

Entity holdings after sale 0 shares TPC RP EPA1 LLC Class A Ordinary Shares following sale

Key Terms

Rule 10b5-1 plan, weighted average price, Class A Ordinary Shares, open-market sale, +1 more

5 terms

Rule 10b5-1 plan financial

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Ordinary Shares financial

"security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"direct_or_indirect: I, nature_of_ownership: By Spouse"

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 04:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last)

(First)

(Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Shares	05/26/2026		S⁽¹⁾		64,399	D	$53.9778⁽²⁾	0	I	TPC RP EPA1 LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Terrance P. Coyne?

Royalty Pharma reported that an entity associated with EVP & CFO Terrance P. Coyne sold 64,399 Class A Ordinary Shares. The sale was executed as an open-market transaction and disclosed in a Form 4 insider trading report filed with regulators.

How many Royalty Pharma (RPRX) shares were sold and at what price?

An entity associated with Terrance P. Coyne sold 64,399 Class A Ordinary Shares at a weighted average price of $53.9778. The Form 4 notes multiple trades occurred in a price range from $53.64 to $54.63 per share during the transaction.

Were the Royalty Pharma (RPRX) insider sales pre-planned under Rule 10b5-1?

Yes. The filing states all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Terrance P. Coyne on February 24, 2026. Such plans pre-schedule trades, reducing the significance of transaction timing as a signal of insider sentiment.

Did Terrance P. Coyne retain any Royalty Pharma (RPRX) shares after this Form 4?

Yes. While TPC RP EPA1 LLC held zero shares after the sale, the Form 4 shows remaining holdings in other accounts. These include direct holdings and indirect holdings via his spouse, an IRA, and his spouse’s IRA, each with reported share balances.

What types of ownership were reported for Royalty Pharma (RPRX) shares in this filing?

The Form 4 reports both direct and indirect ownership for Class A Ordinary Shares. Indirect holdings include shares held by the reporting person’s spouse, the reporting person’s IRA, and the spouse’s IRA, while another indirect account, TPC RP EPA1 LLC, sold all its reported shares.

How is the sale price range for the Royalty Pharma (RPRX) insider transaction described?

The Form 4 lists a weighted average sale price of $53.9778 per share. It explains that the 64,399 shares were sold in multiple trades at prices ranging between $53.64 and $54.63, and detailed breakdowns are available upon written request to the holder.